Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of ranibizumab versus laser photocoagulation for visual impairment due to diabetic macular edema
2009-010825-37Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Novartis. Primary endpoints: Mean change in best-corrected visual acuity at 12 months and Proportion of patients with visual acuity improvement at 12 months. Started Apr 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2009-010825-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010825-37.